2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024 PMID: 39400386, DOI: 10.1111/ejh.14321.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalOS benefitNon-respondersAssociated with improved OSPatients treated with ruxolitinibAssociated with overall survivalAssociated with significant OS benefitImproved overall survivalSignificant OS benefitPERSIST-2Analysis of survivalUnique survival advantagesInhibitor of Janus kinaseJanus kinaseOS curvesRetrospective analysisSurvival advantageMyelofibrosisPacritinibPatientsRuxolitinibPlateletThrombocytopeniaVolume reduction
2020
Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
Schiffer M, Kowalski A, Zhao J, Bewersdorf JP, Lewis RS, Zeidan AM. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis. Drugs Of Today 2020, 56: 755-768. PMID: 33332482, DOI: 10.1358/dot.2020.56.12.3230206.Peer-Reviewed Original ResearchConceptsSecondary myelofibrosisClinical holdSelective Janus kinase 2 inhibitorNovel oral agentsCommon adverse effectsClinical trial dataFurther drug developmentGastrointestinal symptomsLiver transaminasesOral agentsSymptom burdenJanus kinase 2 inhibitorDrug AdministrationMyeloproliferative neoplasmsTrial dataU.S. FoodAdverse effectsKinase 2 inhibitorPhase IIDrug developmentMyelofibrosisSignificant reductionFurther investigationFedratinibSplenomegaly